Safety profile comparing azathioprine and mycophenolate in kidney transplant recipients receiving tacrolimus and corticosteroids

Transplant Infectious Disease

Volumn 15, Issue 4, 2013, Pages 369-378

  Cristelli, M P ^a   Tedesco Silva, H ^a   Medina Pestana, J O ^a   Franco, M F ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Acute rejection; Azathioprine; Immunosuppression; Infection; Kidney transplant; Mycophenolic acid

Indexed keywords

ANTHELMINTIC AGENT; AZATHIOPRINE; BASILIXIMAB; COTRIMOXAZOLE; GANCICLOVIR; ISONIAZID; METHYLPREDNISOLONE; MYCOPHENOLIC ACID; PREDNISONE; TACROLIMUS; THYMOCYTE ANTIBODY;

ACUTE GRAFT REJECTION; ADULT; AGED; ARTICLE; BACTERIAL INFECTION; BONE MARROW TOXICITY; CLINICAL TRIAL (TOPIC); COHORT ANALYSIS; CYTOMEGALOVIRUS INFECTION; DEATH; DRUG BLOOD LEVEL; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL TOXICITY; GRAFT FAILURE; GRAFT RECIPIENT; GRAFT SURVIVAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY BIOPSY; KIDNEY FUNCTION; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LOW RISK POPULATION; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; STRONGYLOIDIASIS; SURVIVAL; TOXOPLASMOSIS; TREATMENT OUTCOME; TUBERCULOSIS; URINARY TRACT INFECTION; VIRUS INFECTION;

EID: 84880796796     PISSN: 13982273     EISSN: 13993062     Source Type: Journal    
DOI: 10.1111/tid.12095     Document Type: Article

References (31)

1. Sayegh MH, Carpenter CB. Transplantation 50 years later: progress, challenges, and promises. N Engl J Med 2004; 351: 2761-2766.
2. Kahan BD. Cyclosporine. N Engl J Med 1989; 321: 1725-1738.
3. Merion RM, White DJG, Thiru S, Evans DB, Calne RY. Cyclosporine: five years' experience in cadaveric renal transplantation. N Engl J Med 1984; 310: 148-154.
4. Pirsch JD, Miller J, Deierhoi MH, Vincenti F, Filo RS. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. Transplantation 1997; 63: 977-983.
5. European Mycophenolate Mofetil Cooperative Study Group. Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. Lancet 1995; 345: 1321-1325.
6. Sollinger HW. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group. Transplantation 1995; 60 (3): 225-232.
7. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. Transplantation 1996; 61 (7): 1029-1037.
8. Halloran P, Mathew T, Tomlanovich S, Groth C, Hooftman L, Barker C. Mycophenolate mofetil in renal allograft recipients: a pooled efficacy analysis of three randomized, double-blind, clinical studies in prevention of rejection. Transplantation 1997; 63 (1): 39-47.
9. Ojo AO, Meier-Krieshe HU, Hanson JA, et al. Mycophenolate mofetil reduces late renal allograft loss independent of acute rejection. Transplantation 2000; 69 (11): 2405-2409.
10. Remuzzi G, Lesti M, Gotti E, et al. Mycophenolate mofetil versus azathioprine for prevention of acute rejection in renal transplantation (MYSS): a randomized trial. Lancet 2004; 364: 503-512.
11. Remuzzi G, Cravedi P, Constantini M, et al. Mycophenolate mofetil versus azathioprine for prevention of chronic allograft dysfunction in renal transplantation: the MYSS follow-up randomized, controlled clinical trial. J Am Soc Nephrol 2007; 18: 1973-1985.
12. Johnson C, Ahsan N, Gonwa T, et al. Randomized trial of tacrolimus (Prograf) in combination with azathioprine or mycophenolate mofetil versus cyclosporine (Neoral) with mycophenolate mofetil after cadaveric kidney transplantation. Transplantation 2000; 69: 834-841.
13. Schold JD, Kaplan B. AZA/Tacrolimus is associated with similar outcomes as MPA/Tacrolimus among renal transplant recipients. Am J Transplant 2009; 9: 2067-2074.
14. Meier-Kriesche HU, Schold JD, Srinivas TR, Kaplan B. Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era. Am J Transplant 2004; 4: 378-383.
15. Opelz G, Dohler B. Influence of immunosuppressive regimens on graft survival and secondary outcomes after kidney transplantation. Transplantation 2009; 87: 795-802.
16. Mengel M, Marwedel M, Radermacher J, et al. Incidence of polyomavirus-nephropathy in renal allografts: influence of modern immunosuppressive drugs. Nephrol Dial Transplant 2003; 18: 1190-1196.
17. Prince O, Savic S, Dickenmann M, Steiger J, Bubendorf L, Mihatsch MJ. Risk factors for polyoma virus nephropathy. Nephrol Dial Transplant 2009; 24: 1024-1033.
18. Racusen LC, Solez K, Colvin RB, et al. The Banff 97 working classification of renal allograft pathology. Kidney Int 1999; 55 (2): 713-723.
19. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41.
20. Sousa SR, Galante NZ, Barbosa DA, Medina-Pestana JO. Incidence of infectious complications and their risk factors in the first year after renal transplantation. J Bras Nefrol 2010; 32 (1): 77-84.
21. Cosio FG, Hickson LJ, Griffin MD, Stegall MD, Kudva Y. Patient survival and cardiovascular risk after kidney transplantation: the challenge of diabetes. Am J Transplant 2008; 8: 593-599.
22. Lentine KL, Gheorghian A, Axelrod D, Kalsekar A, L'italien G, Schnitzler MA. The implications of acute rejection for allograft survival in contemporary U.S. kidney transplantation. Transplantation 2012; 94 (4): 1-8.
23. Meier-Kriesche HU, Chu AH, David KM, Chi-Burris K, Steffen BJ. Switching immunosuppression medications after renal transplantation - a common practice. Nephrol Dial Transplant 2006; 21: 2256-2262.
24. Dudley C, Pohanka E, Riad H, et al. Mycophenolate mofetil substitution for cyclosporine A in renal transplant recipients with chronic progressive allograft dysfunction: the "Creeping Creatinine" study. Transplantation 2005; 79 (4): 466-475.
25. Meier-Kriesche HU, Merville P, Tedesco-Silva H, et al. Mycophenolate mofetil initiation in renal transplant patients at different times posttransplantation: the TranCept Switch Study. Transplantation 2011; 91 (9): 984-990.
26. Weimer R, Deisz S, Dietrich H, et al. Impact of maintenance immunosuppressive regimens - balance between graft protective suppression of immune functions and a near physiological immune response. Transpl Int 2011; 24: 596-609.
27. Programa Nacional de Controle da Tuberculose. Situação Epidemiológica. Portal da Saúde-Ministério da Saúde. Available at: http://portal.saude.gov.br/portal/saude/profissional/area.cfm?id_area=1527 (Accessed 6 February 2011).
28. CDC. Reported tuberculosis in the United States, 2010. Atlanta, GA: US Department of Health and Human Services, CDC; 2011. Available at: http://www.cdc.gov/tb/statistics/reports/2010/default.htm (Accessed 16 September 2012).
29. Cattamanchi A, Smith R, Steingart KR, et al. Interferon-gamma release assays for the diagnosis of latent tuberculosis infection in HIV-infected individuals: a systematic review and meta-analysis. J Acquir Immune Defic Syndr 2011; 56: 230-238.
30. Richeldi L, Losi M, D'Amico R, et al. Performance of tests for latent tuberculosis in different groups of immunocompromised patients. Chest 2009; 136 (1): 198-204.
31. Clayton PA, McDonald SP, Chapman JR, Chadban JR. Mycophenolate versus azathioprine for kidney transplantation: a 15-year follow-up of a randomized trial. Transplantation 2012; 94 (2): 152-158.